Gregory A Denomme

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1785812/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recommendation for validation and quality assurance of nonâ€invasive prenatal testing for foetal blood groups and implications for <scp>IVD</scp> risk classification according to <scp>EU</scp> regulations. Vox Sanguinis, 2022, 117, 157-165.	0.7	7
2	Molecular blood group screening in Omani blood donors. Vox Sanguinis, 2022, 117, 424-430.	0.7	1
3	<scp>SCAR</scp> : The highâ€prevalence antigen 013.008 in the <scp>Scianna</scp> blood group system. Transfusion, 2021, 61, 246-254.	0.8	4
4	Red cell genotyping of rare blood donors: donation behaviour and data visualization. Vox Sanguinis, 2021, 116, 601-608.	0.7	1
5	A pair of <scp>S</scp> â€silencing single nucleotide variants <i>cis</i> â€linked on <scp><i>GYPB</i></scp> . Transfusion, 2021, 61, E34-E36.	0.8	1
6	Effect of cryopreservation on a rare McLeod donor red blood cell concentrate. Immunohematology, 2021, 37, 78-83.	0.2	3
7	Novel <i>KEL*02N</i> allele in Saudi Arabia encoding a Kell null (<scp>K₀</scp>) phenotype. Transfusion, 2021, 61, E49-E50.	0.8	0
8	Generation of â€~designer erythroblasts' lacking one or more blood group systems from CRISPR/Cas9 geneâ€edited humanâ€induced pluripotent stem cells. Journal of Cellular and Molecular Medicine, 2021, 25, 9340-9349.	1.6	9
9	Two Prevalent â^¼100-kb <i>GYPB</i> Deletions Causative of the GPB-Deficient Blood Group MNS Phenotype S–s–U– in Black Africans. Transfusion Medicine and Hemotherapy, 2020, 47, 326-336.	0.7	8
10	Predictive modeling of complex ABO glycan phenotypes by lectin microarrays. Blood Advances, 2020, 4, 3960-3970.	2.5	2
11	Three non-classical mechanisms for anemic disease of the fetus and newborn, based on maternal anti-Kell, anti-Ge3, anti-M, and anti-Jra cases. Transfusion and Apheresis Science, 2020, 59, 102949.	0.5	13
12	<scp>Antiâ€D</scp> selection for <scp>D</scp> assignment among pregnant women and blood donors: impact of the <scp>Crawford</scp> antigen. Transfusion, 2020, 60, 1378-1380.	0.8	1
13	Complement activating ABO anti-A IgM/IgG act synergistically to cause erythrophagocytosis: implications among minor ABO incompatible transfusions. Journal of Translational Medicine, 2020, 18, 216.	1.8	4
14	It's time to phase out "serologic weak D phenotype―and resolve D types with <i>RHD</i> genotyping including weak D type 4. Transfusion, 2020, 60, 855-859.	0.8	27
15	ABO titers: harmonization and identifying clinically relevant ABO antibodies. Transfusion, 2020, 60, 441-443.	0.8	4
16	Fetal inheritance of GP*Mur causing severe HDFN in an unrecognized case of maternal alloimmunization. Transfusion, 2020, 60, 870-874.	0.8	9
17	How to use a cloudâ€based search engine of a centralized donor database to identify historical antigenâ€negative units in hospital inventories. Transfusion, 2020, 60, 414-416.	0.8	2
18	IgG3 antiâ€Kell allotypic variation results in differential antigen binding and phagocytosis. Transfusion, 2020, 60, 688-693.	0.8	3

#	Article	IF	CITATIONS
19	Use of a cloudâ€based search engine of a centralized donor database to identify historical antigenâ€negative units in hospital inventories. Transfusion, 2020, 60, 417-423.	0.8	4
20	Massâ€scale red cell genotyping of blood donors: from data visualization to historical antigen labeling and donor recruitment. Transfusion, 2019, 59, 2768-2770.	0.8	5
21	Performance and reliability of a benchtop automated instrument for transfusion testing: a comparative multicenter clinical study in the US population. Transfusion, 2019, 59, 3511-3518.	0.8	4
22	New <i>RHCE*ce</i> variant allele in African descent holds 105C>T (silent) in cis to 48C in Exon 1 and 733G in Exon 5. Transfusion, 2019, 59, 3039-3040.	0.8	3
23	Validated Reference Panel from Renewable Source of Genomic DNA Available for Standardization of Blood Group Genotyping. Journal of Molecular Diagnostics, 2019, 21, 525-537.	1.2	7
24	International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology: Report of the Dubai, Copenhagen and Toronto meetings. Vox Sanguinis, 2019, 114, 95-102.	0.7	75
25	Trends in antigenâ€negative red blood cell distributions by racial or ethnic groups in the United States. Transfusion, 2018, 58, 145-150.	0.8	10
26	Molecular characterization and multidisciplinary management of Gerbich hemolytic disease of the newborn. Pediatric Blood and Cancer, 2018, 65, e27014.	0.8	3
27	Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline. Transfusion, 2018, 58, 1555-1566.	0.8	55
28	Molecular immunohaematology round table discussions at the AABB Annual Meeting, Orlando 2016. Blood Transfusion, 2018, 16, 447-456.	0.3	1
29	Practical approaches and costs for provisioning safe transfusions during antiâ€CD38 therapy. Transfusion, 2017, 57, 1470-1479.	0.8	27
30	Genetic background of the rare Yus and Gerbich blood group phenotypes: homologous regions of the <i><scp>GYPC</scp></i> gene contribute to deletion alleles. British Journal of Haematology, 2017, 177, 630-640.	1.2	8
31	How do I work up pretransfusion samples containing anti D38?. Transfusion, 2017, 57, 1337-1342.	0.8	18
32	Molecular characterization of three novel weak D type alleles with additional haplotype data on weak D Types 1.2 and 18. Transfusion, 2017, 57, 1092-1093.	0.8	2
33	Costâ€effectiveness of implementing molecular immunohematology. ISBT Science Series, 2017, 12, 223-226.	1.1	3
34	Red cell genotyping precision medicine: a conference summary. Therapeutic Advances in Hematology, 2017, 8, 277-291.	1.1	16
35	The first reported case of concurrent trimethoprimâ€sulfamethoxazole–induced immune hemolytic anemia and thrombocytopenia. Transfusion, 2017, 57, 2937-2941.	0.8	7
36	Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions. Blood Advances, 2017, 1, 1977-1982.	2.5	7

#	Article	IF	CITATIONS
37	Unusual serological findings associated with ceftriaxoneâ€induced immune hemolytic anemia in a child with disseminated lowâ€grade glioma. Pediatric Blood and Cancer, 2016, 63, 1852-1855.	0.8	3
38	The <i>DAU</i> cluster: a comparative analysis of 18 <i>RHD</i> alleles, some forming partial D antigens. Transfusion, 2016, 56, 2520-2531.	0.8	17
39	International society of blood transfusion working party on red cell immunogenetics and terminology: report of the Seoul and London meetings. ISBT Science Series, 2016, 11, 118-122.	1.1	56
40	Molecular immunohaematology round table discussions at the AABB Annual Meeting, Anaheim 2015. Blood Transfusion, 2016, 14, 557-565.	0.3	6
41	Implementing massâ€scale red cell genotyping at a blood center. Transfusion, 2015, 55, 2610-2615.	0.8	70
42	Barriers to using molecularly typed minority red blood cell donors in support of chronically transfused adult patients with sickle cell disease. Transfusion, 2015, 55, 1399-1406.	0.8	24
43	The future of red blood cell alloimmunization risk reduction. Transfusion, 2015, 55, 220-221.	0.8	10
44	A multicenter study on the performance of a fully automated, walkâ€away highâ€ŧhroughput analyzer for pretransfusion testing in the US population. Transfusion, 2015, 55, 1522-1528.	0.8	12
45	<i>RHCE*cE94G</i> encodes variable expression of c (RH4). Transfusion, 2015, 55, 2519-2520.	0.8	2
46	Integration of red cell genotyping into the blood supply chain: a population-based study. Lancet Haematology,the, 2015, 2, e282-e288.	2.2	66
47	lt's time to phase in <i><scp>RHD</scp></i> genotyping for patients with a serologic weak <scp>D</scp> phenotype. Transfusion, 2015, 55, 680-689.	0.8	157
48	Kell and Kx blood group systems. Immunohematology, 2015, 31, 14-19.	0.2	29
49	Mass-scale donor red cell genotyping using real-time array technology. Immunohematology, 2015, 31, 69-74.	0.2	12
50	Molecular immunohaematology round table discussions at the AABB Annual Meeting, Denver 2013. Blood Transfusion, 2015, 13, 514-20.	0.3	6
51	RhD Specific Antibodies Are Not Detectable in HLA-DRB11501*Mice Challenged with Human RhD Positive Erythrocytes. Advances in Hematology, 2014, 2014, 1-7.	0.6	4
52	Molecular immunohaematology round table discussions at the AABB Annual Meeting, Boston 2012. Blood Transfusion, 2014, 12, 280-6.	0.3	10
53	Antibodyâ€mediated glycophorin <scp>C</scp> coligation on <scp>K</scp> 562 cells induces phosphatidylserine exposure and cell death in an atypical apoptotic process. Transfusion, 2013, 53, 2134-2140.	0.8	5
54	Prospects for the provision of genotyped blood for transfusion. British Journal of Haematology, 2013, 163, 3-9.	1.2	36

#	Article	IF	CITATIONS
55	Allo―and autoantiâ€Ð in weak D types and in partial D. Transfusion, 2012, 52, 2067-2069.	0.8	9
56	Microfluidic approach to genotyping human platelet antigens. IET Nanobiotechnology, 2012, 6, 33.	1.9	0
57	Editorial Comment. Transfusion and Apheresis Science, 2011, 44, 49.	0.5	Ο
58	Molecular basis of blood group expression. Transfusion and Apheresis Science, 2011, 44, 53-63.	0.5	36
59	DNA-based methods in the immunohematology reference laboratory. Transfusion and Apheresis Science, 2011, 44, 65-72.	0.5	47
60	Mass-scale red cell genotyping of blood donors. Transfusion and Apheresis Science, 2011, 44, 93-99.	0.5	31
61	Titers of ABO antibodies in group O blood donors. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 250-251.	0.7	4
62	Massâ€scale highâ€throughput multiplex polymerase chain reaction for human platelet antigen singleâ€nucleotide polymorphisms screening of apheresis platelet donors. Transfusion, 2011, 51, 2028-2033.	0.8	16
63	Antiâ€glycophorin C induces mitochondrial membrane depolarization and a loss of extracellular regulated kinase 1/2 protein kinase activity that is prevented by pretreatment with cytochalasin D: implications for hemolytic disease of the fetus and newborn caused by antiâ€Ge3. Transfusion, 2010, 50, 1761-1765	0.8	7
64	Consortium for Blood Group Genes (CBGG): 2009 report. Immunohematology, 2010, 26, 47-50.	0.2	10
65	Genotyping for red blood cell polymorphisms. Vox Sanguinis, 2009, 96, 167-179.	0.7	22
66	The proximal cisâ€regulatory region of the <i>RHD</i> / <i>RHCE</i> promoter is 105 bp and contains a 55â€bp core devoid of known binding motifs but necessary for transcription. Transfusion, 2009, 49, 1361-1369.	0.8	3
67	Single Base Extension in Multiplex Blood Group Genotyping. Methods in Molecular Biology, 2009, 496, 15-24.	0.4	2
68	Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models?. Current Opinion in Hematology, 2009, 16, 488-496.	1.2	20
69	Consortium for Blood Group Genes (CBGG): 2008 report. Immunohematology, 2009, 25, 75-80.	0.2	4
70	Rh discrepancies caused by variable reactivity of partial and weak D types with different serologic techniques. Transfusion, 2008, 48, 473-478.	0.8	37
71	Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time. Transfusion, 2008, 48, 2461-2475.	0.8	73
72	IFN-Î ³ treated monocyte/macrophage phagocytosis of red cells sensitized with IgG1 and IgG3 Anti-D containing identical immunoglobulin variable region genes. Transfusion and Apheresis Science, 2008, 39, 37-44.	0.5	2

#	Article	IF	CITATIONS
73	Hemolytic Disease of the Fetus and Newborn Due to Anti-Ge3: Combined Antibody-Dependent Hemolysis and Erythroid Precursor Cell Growth Inhibition. American Journal of Perinatology, 2008, 25, 541-545.	0.6	14
74	On the Complexity of D Antigen Typing: A Handy Decision Tree in the Age of Molecular Blood Group Diagnostics. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 746-752.	0.3	36
75	Small world – Advance of microarrays: Current status and future trends. Transfusion and Apheresis Science, 2007, 36, 201-206.	0.5	7
76	Predictive blood group genetics in hemolytic disease of the fetus and newborn: a 10â€year review of a laboratory evaluation of amniotic fluidâ€derived DNA. Prenatal Diagnosis, 2007, 27, 1017-1023.	1.1	2
77	The above letter was sent to Branch et al.; Drs Branch and Denomme offered the following reply Transfusion, 2007, 47, 351-352.	0.8	0
78	Fetal blood group genotyping. Transfusion, 2007, 47, 64S-68S.	0.8	14
79	Platelet and Leukocyte FcÎ ³ Receptors in Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 187-208.	0.0	3
80	Detection of antibodies reacting with the antithetical duffy blood group antigens Fya and Fyb using recombinant fusion proteins containing the duffy extracellular domain. Transfusion and Apheresis Science, 2006, 35, 207-216.	0.5	5
81	Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor l ² and prostaglandin E2. Transfusion, 2006, 46, 1316-1322.	0.8	28
82	Inhibition of erythroid progenitor cell growth by anti-Ge3. British Journal of Haematology, 2006, 133, 443-444.	1.2	19
83	Amino-acid substitution in the disordered loop of blood group B-glycosyltransferase enzyme causes weak B phenotype. Transfusion, 2005, 45, 1178-1182.	0.8	9
84	Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion, 2005, 45, 1554-1560.	0.8	105
85	Chemical compounds that target thiol-disulfide groups on mononuclear phagocytes inhibit immune mediated phagocytosis of red blood cells. Transfusion, 2005, 45, 384-393.	0.8	34
86	High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes. Transfusion, 2005, 45, 660-666.	0.8	131
87	The Mechanism of Rh-Immune Globulin Prophylaxis Involves Significant Increases in the Immunosuppressive Cytokines TGFβ and PGE2 Blood, 2005, 106, 558-558.	0.6	5
88	Maternal ABO-mismatched blood for intrauterine transfusion of severe hemolytic disease of the newborn due to anti-Rh17. Transfusion, 2004, 44, 1357-1360.	0.8	37
89	ABO sequence analysis in a family with weak expression of blood group B. Transfusion, 2004, 44, 1394-1395.	0.8	9
90	The structure and function of the molecules that carry human red blood cell and platelet antigensâ~†. Transfusion Medicine Reviews, 2004, 18, 203-231.	0.9	34

#	Article	IF	CITATIONS
91	FcÎ ³ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. British Journal of Haematology, 2003, 120, 135-141.	1.2	71
92	Synonymous nucleotide substitutions in the neonatal Fc receptor. Immunogenetics, 2002, 54, 139-140.	1.2	3
93	Novel 3' Rhesus box sequences confound RHD zygosity assignment. Transfusion, 2002, 42, 645-650.	0.8	53
94	In Silico Analysis in Transfusion Medicine. Vox Sanguinis, 2002, 83, 111-113.	0.7	5
95	Protocols. , 2000, , 19-65.		5
96	Red Cell Blood Groups. , 2000, , 67-139.		1
97	RhD status of a fetus at risk for haemolytic disease with a discrepant maternal DNA-based RhD genotype. , 1999, 19, 424-427.		5
98	An Adenine Trimer Precedes a C/G Polymorphism in the 3′-Amplimer Region of the Human Platelet Glycoprotein IIIa Intron 6 CT Repeat. Human Heredity, 1998, 48, 115-118.	0.4	2
99	Factor V Leiden and Thrombotic Complications in Heparin-induced Thrombocytopenia. Thrombosis and Haemostasis, 1998, 79, 50-53.	1.8	37
100	Activation of platelets by sera containing igg1 heparin-dependent antibodies: an explanation for the predominance of the Fcl³rlla "low responder―(his131) gene in patients with heparin-induced thrombocytopenia. Translational Research, 1997, 130, 278-284.	2.4	88
101	Maternal immunization to Gov system alloantigens on human platelets. Transfusion, 1997, 37, 823-828.	0.8	45
102	A diagnostic test for heparinâ€induced thrombocytopenia: detection of platelet microparticles using flow cytometry. British Journal of Haematology, 1996, 95, 724-731.	1.2	125
103	The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis. British Journal of Haematology, 1995, 91, 742-746.	1.2	17
104	The role of the immunoglobulin heavy chain in human anti-dna antibody binding specificity. Arthritis and Rheumatism, 1995, 38, 389-395.	6.7	11
105	The cDNA Sequence of Human Endothelial Cell Multimerin. Journal of Biological Chemistry, 1995, 270, 18246-18251.	1.6	62
106	The Development of a Bacteriophage Expression Vector for Cloning Immunoglobulin Variable Region Genes from Bâ€Cell Genomic DNA ^a . Annals of the New York Academy of Sciences, 1995, 764, 580-582.	1.8	0
107	Immunoglobulin V Sequences of Two Human Antiplatelet Monoclonal Autoantibodies Derived from B Cells of Normal Origin. Journal of Autoimmunity, 1994, 7, 521-535.	3.0	20
108	Immunoglobulin V region heavy and light chain gene sequences of the lymphoblastoid cell line GM 4672. Human Antibodies, 1993, 4, 98-103.	0.6	1

#	Article	IF	CITATIONS
109	Immunoglobulin V region heavy and light chain gene sequences of the lymphoblastoid cell line GM 4672. Human Antibodies and Hybridomas, 1993, 4, 98-103.	0.1	0
110	The production of human monoclonal antiplatelet auto-antibodies derived from human lymphocytes of normal origin: reactivity to DNA, anionic phospholipids and platelet proteins. British Journal of Haematology, 1992, 82, 99-106.	1.2	8
111	A human monoclonal autoantibody to platelet glycoprotein IIb derived from normal human lymphocytes. Blood, 1992, 79, 447-51.	0.6	4
112	Comparison of the measurement of surface or total platelet-associated IgG in the diagnosis of immune thrombocytopenia. American Journal of Hematology, 1985, 18, 1-5.	2.0	21
113	The production of platelet controls for assays quantitating platelet- associated IgG. Transfusion, 1983, 23, 516-518.	0.8	3
114	The Measurement of Plateiet-Associated IgG Using an Immunoradiometric Assay. Journal of Immunoassay, 1983, 4, 65-82.	0.3	14
115	A case of Tn polyagglutination discovered by an <scp>ABO</scp> blood group discrepancy. Transfusion, 0, , .	0.8	1